Slide
Slide

Central Nervous System Portfolio

Preclinical

Phase I

Phase II

Phase III

TNX-102 SL   Fibromyalgia (FM)
Two statistically significant Phase III studies completed, expect to file NDA in 2H 2024

Mid-Phase III

TNX-102 SL   Acute Stress Disorder
Phase II ready

Phase II

TNX-1300   Cocaine Intoxication / Overdose
Phase II ongoing — Breakthrough Therapy Designation

Mid-Phase II

Immunology Portfolio

Preclinical

Phase I

Phase II

Phase III

TNX-1500   Organ Transplant Rejection / Autoimmune Disorders
Phase I  — Clinical phase complete

Preclinical

TNX-1700  Gastric and Colorectal Cancer
Preclinical

Preclinical

Infectious Disease Portfolio

Preclinical

Phase I

Phase II

Phase III

TNX-801  Smallpox and Monkeypox Preventing Vaccine
Preclinical

Preclinical

TNX-1800   COVID-19 Vaccine
Preclinical

Preclinical

Rare Disease Portfolio

Preclinical

Phase I

Phase II

Phase III

TNX-2900   Prader-Willi Syndrome
Phase II ready – FDA Orphan Drug and Rare Pediatric Disease Designation

Preclinical